Enveric Biosciences, Inc (ENVB) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Enveric Biosciences, Inc stock $0.77, price $1.44, that is 46.9% below the price, quality 36 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Enveric Biosciences, Inc
ENVB · USFar too expensive (fair value 47% below the price), weak company and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range $1.27 – $31,500 · fair‑value band $0.5015 – $0.9520 · the $1.44 price screens above the $0.7650 fair value. As of Nov 14, 2026.
Every Wednesday you see whether Enveric Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States.
Show moreShow less
Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.
The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Stock analysis
Enveric Biosciences, Inc (ENVB) currently trades at $1.44, while our model-based Fair Value estimate is $0.7650, 47% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.5015 (bear) to $0.9520 (bull), the price of $1.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Enveric Biosciences, Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$12.1M in FY2025.
Key figures
Market cap $6.4M Micro · P/S ratio 0.19 · EPS (TTM) $−13.01 · Return on equity −170% · Return on assets (EBIT) −213% (5-year average) · Revenue (TTM) $35.4M · Revenue growth (YoY) −7.3% · Free cash flow −$8.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).
What moves the price
The share trades about 86% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −47%, ENVB screens richer than that median.
Fair Value models
All 1 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Enveric Biosciences, Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs ENVB |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs ENVB |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs ENVB |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs ENVB |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs ENVB |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs ENVB |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs ENVB |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs ENVB |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs ENVB |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs ENVB |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Enveric Biosciences, Inc (ENVB) overvalued or undervalued?
What is the fair value of ENVB?
What is the quality score of ENVB?
What is the price target for Enveric Biosciences, Inc (ENVB)?
What is the Enveric Biosciences, Inc stock forecast for 2026?
What is the revenue of Enveric Biosciences, Inc (ENVB)?
What is the intrinsic value of Enveric Biosciences, Inc (ENVB)?
Is Enveric Biosciences, Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ENVB?
How much is Enveric Biosciences, Inc worth?
What do the bullish and bearish scenarios say about ENVB?
How solid is the balance sheet of Enveric Biosciences, Inc (ENVB)?
How far is ENVB from its 52-week high?
Which stocks are comparable to Enveric Biosciences, Inc?
Is Enveric Biosciences, Inc stock attractive at the current price?
How is the fair value of ENVB calculated?
Is it still worth investing in stocks now?
What is the share price of Enveric Biosciences, Inc (ENVB)?
What should I pay attention to with Enveric Biosciences, Inc right now?
Key figures of Enveric Biosciences, Inc
How large is the market capitalisation of Enveric Biosciences, Inc (ENVB)?
What is the P/S ratio of Enveric Biosciences, Inc (ENVB)?
What are the earnings per share of Enveric Biosciences, Inc (ENVB)?
What is the return on equity of Enveric Biosciences, Inc (ENVB)?
What is the EBIT return on assets of Enveric Biosciences, Inc (ENVB)?
How fast is revenue growing at Enveric Biosciences, Inc (ENVB)?
How much free cash flow does Enveric Biosciences, Inc (ENVB) generate?
How much net cash does Enveric Biosciences, Inc (ENVB) hold?
Watch Enveric Biosciences, Inc in the live analysis
One click puts Enveric Biosciences, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.